PRAX announces Q3 FY2025 results via furnished Exhibit 99.1

Q: Which period do the results cover for PRAX (PRAX)?

The results cover the quarter ended September 30, 2025 .

Q: How were the PRAX results provided?

Through a press release furnished as Exhibit 99.1 to the report.

Q: Is the PRAX press release considered filed under Section 18?

No. The Item 2.02 information and Exhibit 99.1 are furnished, not filed , and are not subject to Section 18 of the Exchange Act.

Q: What is PRAX’s stock exchange and ticker?

PRAX’s common stock trades on The Nasdaq Global Select Market under the symbol PRAX .

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Praxis Precision Medicines (PRAX) reported that it announced its financial results for the quarter ended September 30, 2025. The company furnished a press release detailing these results as Exhibit 99.1.

The information under Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liability, nor incorporated by reference unless specifically stated. PRAX’s common stock trades on The Nasdaq Global Select Market under the symbol PRAX.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/05/2025 - 08:03 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2025

PRAXIS PRECISION MEDICINES, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-39620	47-5195942
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Praxis Precision Medicines, Inc.

99 High Street, 30th Floor

Boston, Massachusetts 02110

(Address of principal executive offices, including zip code)

(617) 300-8460

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trade

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share

PRAX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 5, 2025, Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025. A copy of the press release containing these announcements is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”).

The information in Item 2.02 of this Current Report and Exhibit 99.1 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall any of it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.						Description

99.1						Press Release, dated November 5, 2025

104						Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	PRAXIS PRECISION MEDICINES, INC.

Date: November 5, 2025	By:	/s/ Marcio Souza
		Marcio Souza
		Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did PRAX announce in this 8-K?

PRAX announced its financial results for the quarter ended September 30, 2025 and furnished a related press release as Exhibit 99.1.

Which period do the results cover for PRAX (PRAX)?

The results cover the quarter ended September 30, 2025.

How were the PRAX results provided?

Through a press release furnished as Exhibit 99.1 to the report.

Is the PRAX press release considered filed under Section 18?

No. The Item 2.02 information and Exhibit 99.1 are furnished, not filed, and are not subject to Section 18 of the Exchange Act.

What is PRAX’s stock exchange and ticker?

PRAX’s common stock trades on The Nasdaq Global Select Market under the symbol PRAX.

When was the announcement made?

On November 5, 2025.